Pharmaceuticals
Research & Development
Tokyo New Drug Research Laboratories and Fuji Laboratory are the core centers for our research and development activities in Japan.
At the Tokyo New Drug Research Laboratories we conduct extensive research activities, including searching for new materials and product opportunities and their biological screening, molecular design, and preclinical studies such as biokinetic studies of medicine.
The Fuji Laboratory has two research divisions: 1) safety research and drug formulation research, where researchers are dedicated to product safety testing, and 2) research on drug delivery systems (DDS) for efficiently delivering drugs to the target site, development of new dosage forms, development of over-the-counter (OTC) drugs, and production of investigational agents.
Livalo® is a prescription drug for the treatment of dyslipidemia developed in Japan by Kowa and with its proven efficacy it has grown into our global product currently marketed in the United States and Asia. Further launches are expected in Europe and other regions in the near future.
Target Areas of R&D
- 1. Drug Discovery
- Arteriosclerosis
- Diabetes
- Immunologic and inflammation
- Ophthalmology
- 2. Innovative Formulation
- Oral
- Dermatological
- Ophthalmic
- 3. Neo Generics
- Value-added pharmaceuticals
Pipeline
Last Updated:May, 2012.
| Development Code / Generic Name (Administration) |
Country / Region | Stage (Launched / Approved) |
Indications | Category |
| NK-104 / Pitavastatin(oral) |
Japan | Launched | Dyslipidemia | HMG-CoA reductase inhibitor |
| US | ||||
| China | ||||
| Korea | ||||
| Indonesia | ||||
| Thailand | ||||
| Spain | ||||
| Portugal | ||||
| Lebanon | ||||
| Mexico | ||||
| [Asia,Oseania] | Approved | |||
| Taiwan | ||||
| Australia | ||||
| [Europe] | ||||
| Austria | ||||
| Belgium | ||||
| Cyprus | ||||
| Finland | ||||
| France | ||||
| Germany | ||||
| Greece | ||||
| Ireland | ||||
| Netherlands | ||||
| Norway | ||||
| Poland | ||||
| Sweden | ||||
| UK |
Last Updated:May, 2012.
| Development Code / Generic Name (Administration) |
Country / Region | Stage | Indications | Category |
| NK-104 / Pitavastatin(oral) |
Italy | Filed | Dyslipidemia | HMG-CoA reductase inhibitor |
| Latin America (excluding Mexico) |
||||
| Middle East (excluding Lebanon) |
Preparing application |
|||
| North Africa | ||||
| NIK-333/ Peretinoin(oral) |
Japan | PIII | Prevention of Recurrent of Liver Cancer | Apoptosis inducer |
| SK-0403(oral) * | Japan | Preparing application |
Type 2 Diabetes Mellitus | DPP-4 inhibitor |
| US | PII | |||
| EU | PII | |||
| K-134(oral) | Japan | PII | Arteriosclerosis Obliterans | Antiplatelet agent |
| US | PII | |||
| K-604(oral) | US | PII | Atherosclerosis | ACAT-1 inhibitor |
| K-115(eye drop) | Japan | PIII | Glaucoma, Ocular Hypertension | Rho kinase inhibitor |
| K-877(oral) | Japan | PII | Dyslipidemia | PPAR-α agonist |
| EU | PI | |||
| K-828-AB(oral) | Japan | PII | BPSD | GABA transaminase inhibitor etc. |
*Co-developed with SANWA KAGAKU KENKYUSHO CO., LTD.